Navigation Links
Xanodyne Announces New Executive Team Members
Date:7/13/2009

NEWPORT, Ky., July 13 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, today announced the appointment of three new members to its executive management team. Joining the company are Natasha Giordano, Chief Commercial Officer; Rita O'Connor, Chief Financial & Information Officer; and Peter Wentworth, Senior Vice President, Human Resources.

Commenting on these appointments, CEO Michael J. Valentino said, "I am excited to welcome Natasha, Rita, and Peter to the Xanodyne management team. Each of them brings a diverse and proven track record of building and leading high growth organizations within the pharmaceutical industry. Their collective experience should contribute significantly to the anticipated rapid growth and commercial success of our company."

Ms. Giordano has more than 25 years of experience in the healthcare and pharmaceutical industry and most recently served as President Americas at Cegedim Dendrite, a global sales and marketing solutions and information company specializing in the pharmaceutical industry. Her depth of experience includes senior leadership positions in general management, marketing, compliance, and sales at major pharmaceutical companies including Pfizer and Parke-Davis.

Ms. O'Connor joins Xanodyne from NPS Pharmaceuticals where she served as Vice President, Finance. Previously, she was Chief Financial Officer and Treasurer at Adams Respiratory Therapeutics. With nearly 20 years of finance and accounting experience in the pharmaceutical industry, O'Connor is a certified public accountant and has held leadership positions at Schering-Plough and Deloitte & Touche. She also serves on the Board of Directors at the Essential Group Inc.

Mr. Wentworth has extensive experience within the field of human resources, including more than 25 years working in global healthcare and consumer products industries. Most recently he was Executive Vice President, Human Resources at Adams Respiratory Therapeutics. Wentworth is a seasoned business leader, who has held a broad range of positions at major global companies such as Pfizer, Warner-Lambert, and PepsiCo.

About Xanodyne
Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of products consisting of FDA approved pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
2. Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference
3. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
6. Mirixa Corporation Announces Key New Hires
7. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
8. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
9. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
10. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
11. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... and GAITHERSBURG, Md. , Jan. ... and Altimmune, Inc., a privately-held immunotherapeutics company targeting ... definitive agreement for the merger of PharmAthene and ... include Novartis Venture Fund, HealthCap, Truffle Capital and ... fully-integrated and diversified immunotherapeutics company with four clinical ...
(Date:1/19/2017)... MD (PRWEB) , ... January 18, 2017 , ... ... the National Institutes of Health (NIH) to update its Data Sharing Policy. Specifically, ... “scoreable” element of grant applications subject to the existing policy. AMIA recommended that ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
(Date:1/19/2017)... 2017 Acupath Laboratories, Inc., a leading provider ... an Executive Committee that will guide the company,s vision ... John Cucci , a 15-year veteran of the anatomic ... Development to Chief Sales Officer .  Prior to ... senior sales leadership roles at several leading lab industry ...
Breaking Biology Technology:
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/6/2017)... Calif. , Jan. 5, 2017  Delta ID ... its iris scanning technology for automotive at CES® 2017. ... GNTX ) to demonstrate the use of iris ... identify and authenticate the driver in a car, and ... during the driving experience. Delta ID and ...
(Date:1/4/2017)... Jan. 4, 2017  CES 2017 – Valencell ... technology, today announced the launch of two new ... the highly-accurate biometric sensor modules that incorporate the ... experience and expertise. The two new designs include ... for hearables, and Benchmark BW2.0, a 2-LED version ...
Breaking Biology News(10 mins):